- Home
- AXSM vs LEGN Comparison
AXSM vs LEGN Comparison
Compare AXSM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXSM
- LEGN
- Stock Information
- Founded
- AXSM 2012
- LEGN 2014
- Country
- AXSM United States
- LEGN United States
- Employees
- AXSM N/A
- LEGN N/A
- Industry
- AXSM Biotechnology: Pharmaceutical Preparations
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- AXSM Health Care
- LEGN Health Care
- Exchange
- AXSM Nasdaq
- LEGN Nasdaq
- Market Cap
- AXSM 5.9B
- LEGN 6.3B
- IPO Year
- AXSM 2015
- LEGN 2020
- Fundamental
- Price
- AXSM $118.87
- LEGN $32.29
- Analyst Decision
- AXSM Strong Buy
- LEGN Strong Buy
- Analyst Count
- AXSM 19
- LEGN 12
- Target Price
- AXSM $174.26
- LEGN $73.36
- AVG Volume (30 Days)
- AXSM 472.4K
- LEGN 1.2M
- Earning Date
- AXSM 11-03-2025
- LEGN 11-11-2025
- Dividend Yield
- AXSM N/A
- LEGN N/A
- EPS Growth
- AXSM N/A
- LEGN N/A
- EPS
- AXSM N/A
- LEGN N/A
- Revenue
- AXSM $495,033,000.00
- LEGN $796,838,000.00
- Revenue This Year
- AXSM $63.62
- LEGN $69.31
- Revenue Next Year
- AXSM $55.72
- LEGN $52.73
- P/E Ratio
- AXSM N/A
- LEGN N/A
- Revenue Growth
- AXSM 69.83
- LEGN 74.75
- 52 Week Low
- AXSM $75.56
- LEGN $27.34
- 52 Week High
- AXSM $139.13
- LEGN $51.77
- Technical
- Relative Strength Index (RSI)
- AXSM 53.69
- LEGN 32.97
- Support Level
- AXSM $117.50
- LEGN $31.18
- Resistance Level
- AXSM $122.14
- LEGN $32.62
- Average True Range (ATR)
- AXSM 2.97
- LEGN 0.98
- MACD
- AXSM -0.29
- LEGN -0.07
- Stochastic Oscillator
- AXSM 44.79
- LEGN 10.44
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.